WuXi Biologics Secures Leading ESG Assessment from Sustainalytics
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has once again proven its commitment to environmental, social, and governance (ESG) practices by earning a top ESG ranking among more than 15,000 companies evaluated across industries worldwide.
Morningstar Sustainalytics, a leading ESG data, research, and ratings firm, has granted WuXi Biologics the highest negligible-risk rating in 2025, placing the company in the top 1% globally. This prestigious recognition underscores WuXi Biologics’ leadership in managing ESG risks with the lowest risk exposure and strongest risk management score within Sustainalytics' two-dimensional framework.
Dr. Chris Chen, CEO and Chairman of the ESG Committee at WuXi Biologics, commented on the negligible-risk rating, stating, "We are honoured to receive this recognition from Morningstar Sustainalytics, which reflects our unwavering commitment to ESG excellence. This achievement motivates us to continue driving innovation aimed at a healthier future with a strong focus on long-term value creation."
WuXi Biologics' ESG achievements and recognitions span five consecutive years, making it an Industry and Regional ESG Top-Rated Company. The company has also received the MSCI AAA rating, the EcoVadis Platinum Medal for two consecutive years, and inclusion in the Dow Jones Sustainability Indices, underscoring global recognition for its sustainability commitment.
Moreover, WuXi Biologics has been acknowledged as a leader in Green CRDMO, driving innovation aimed at a healthier future. The company is also listed in the Hang Seng ESG 50 Index, the FTSE4Good Index Series, and has been selected as a Constituent of the CDP Water Security "A list" and has received an A- CDP Climate Change leadership-level score since 2023.
WuXi Biologics participates in the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), further demonstrating its dedication to sustainability and responsible investment standards.
For more information about WuXi Biologics and its ESG initiatives, visit www.wuxibiologics.com. The company's ESG Risk Ratings are categorized across five risk levels, from negligible to severe, and evaluate over 20 material ESG issues through over 200 indicators. WuXi Biologics has achieved the lowest level of risk exposure under this assessment framework, earning the strongest risk management score. The company has also been rated as Prime by ISS ESG Corporate Rating.
In conclusion, WuXi Biologics exemplifies excellence in ESG practices among global pharmaceutical and biotech companies, committing to sustainability and responsible investment standards recognized by top-tier rating agencies.
In the realm of ESG practices, WuXi Biologics has demonstrated its leadership by achieving the highest negligible-risk rating from Morningstar Sustainalytics in 2025, a recognition that places the company among the top 1% globally. Furthermore, the company's remarkable commitments to environmental science and technology, as part of its broader ESG initiatives, have earned it numerous accolades, positioning it as a prime example of a sustainable and responsible biotech entity.
